228 related articles for article (PubMed ID: 29615836)
1. Long-term evolution of lung function in individuals with alpha-1 antitrypsin deficiency from the Spanish registry (REDAAT).
Esquinas C; Serreri S; Barrecheguren M; Rodriguez E; Nuñez A; Casas-Maldonado F; Blanco I; Pirina P; Lara B; Miravitlles M
Int J Chron Obstruct Pulmon Dis; 2018; 13():1001-1007. PubMed ID: 29615836
[TBL] [Abstract][Full Text] [Related]
2. Decline in FEV
Hiller AM; Piitulainen E; Jehpsson L; Tanash H
Int J Chron Obstruct Pulmon Dis; 2019; 14():1075-1083. PubMed ID: 31213789
[No Abstract] [Full Text] [Related]
3. Exacerbations and duration of smoking abstinence are associated with the annual loss of FEV
Fähndrich S; Bernhard N; Lepper PM; Vogelmeier C; Seibert M; Wagenpfeil S; Bals R
Respir Med; 2017 Aug; 129():8-15. PubMed ID: 28732839
[TBL] [Abstract][Full Text] [Related]
4. Spanish Registry of Patients With Alpha-1 Antitrypsin Deficiency; Comparison of the Characteristics of PISZ and PIZZ Individuals.
Lara B; Miravitlles M
COPD; 2015 May; 12 Suppl 1():27-31. PubMed ID: 25938288
[TBL] [Abstract][Full Text] [Related]
5. Deterioration of quality of life is associated with the exacerbation frequency in individuals with alpha-1-antitrypsin deficiency - analysis from the German Registry.
Bernhard N; Lepper PM; Vogelmeier C; Seibert M; Wagenpfeil S; Bals R; Fähndrich S
Int J Chron Obstruct Pulmon Dis; 2017; 12():1427-1437. PubMed ID: 28553095
[TBL] [Abstract][Full Text] [Related]
6. Individualized lung function trends in alpha-1-antitrypsin deficiency: a need for patience in order to provide patient centered management?
Stockley RA; Edgar RG; Pillai A; Turner AM
Int J Chron Obstruct Pulmon Dis; 2016; 11():1745-56. PubMed ID: 27536086
[TBL] [Abstract][Full Text] [Related]
7. The impact of smoke exposure on the clinical phenotype of alpha-1 antitrypsin deficiency in Ireland: exploiting a national registry to understand a rare disease.
O'Brien ME; Pennycooke K; Carroll TP; Shum J; Fee LT; O'Connor C; Logan PM; Reeves EP; McElvaney NG
COPD; 2015 May; 12 Suppl 1():2-9. PubMed ID: 25938284
[TBL] [Abstract][Full Text] [Related]
8. Maximal mid-expiratory flow detects early lung disease in α
Stockley JA; Ismail AM; Hughes SM; Edgar R; Stockley RA; Sapey E
Eur Respir J; 2017 Mar; 49(3):. PubMed ID: 28356373
[TBL] [Abstract][Full Text] [Related]
9. Treatment of lung disease in alpha-1 antitrypsin deficiency: a systematic review.
Edgar RG; Patel M; Bayliss S; Crossley D; Sapey E; Turner AM
Int J Chron Obstruct Pulmon Dis; 2017; 12():1295-1308. PubMed ID: 28496314
[TBL] [Abstract][Full Text] [Related]
10. Factors associated with the evolution of lung function in patients with alpha-1 antitrypsin deficiency in the Spanish registry.
Tirado-Conde G; Lara B; Casas F; Blanco I; Bustamante A; Cadenas S; Martínez MT; Lázaro L; Torres M; Hernández Pérez JM; Vidal R; Miravitlles M
Arch Bronconeumol; 2011 Oct; 47(10):495-503. PubMed ID: 21798656
[TBL] [Abstract][Full Text] [Related]
11. PiSZ alpha-1 antitrypsin deficiency (AATD): pulmonary phenotype and prognosis relative to PiZZ AATD and PiMM COPD.
Green CE; Vayalapra S; Hampson JA; Mukherjee D; Stockley RA; Turner AM
Thorax; 2015 Oct; 70(10):939-45. PubMed ID: 26141072
[TBL] [Abstract][Full Text] [Related]
12. Health status and lung function in the Swedish alpha 1-antitrypsin deficient cohort, identified by neonatal screening, at the age of 37-40 years.
Piitulainen E; Mostafavi B; Tanash HA
Int J Chron Obstruct Pulmon Dis; 2017; 12():495-500. PubMed ID: 28203073
[TBL] [Abstract][Full Text] [Related]
13. Health-related quality of life in patients with alpha-1 antitrypsin deficiency: the French experience.
Gauvain C; Mornex JF; Pison C; Cuvelier A; Balduyck M; Pujazon MC; Fournier M; AitIlalne B; Thabut G
COPD; 2015 May; 12 Suppl 1():46-51. PubMed ID: 25938292
[TBL] [Abstract][Full Text] [Related]
14. Intensive smoking diminishes the differences in quality of life and exacerbation frequency between the alpha-1-antitrypsin deficiency genotypes PiZZ and PiSZ.
Bernhard N; Lepper PM; Vogelmeier C; Seibert M; Wagenpfeil S; Bals R; Fähndrich S
Respir Med; 2017 Sep; 130():1-8. PubMed ID: 29206626
[TBL] [Abstract][Full Text] [Related]
15. Matrix metalloproteinase-9 predicts pulmonary status declines in α1-antitrypsin deficiency.
Omachi TA; Eisner MD; Rames A; Markovtsova L; Blanc PD
Respir Res; 2011 Mar; 12(1):35. PubMed ID: 21429222
[TBL] [Abstract][Full Text] [Related]
16. Clarifying the Risk of Lung Disease in SZ Alpha-1 Antitrypsin Deficiency.
Franciosi AN; Hobbs BD; McElvaney OJ; Molloy K; Hersh C; Clarke L; Gunaratnam C; Silverman EK; Carroll TP; McElvaney NG
Am J Respir Crit Care Med; 2020 Jul; 202(1):73-82. PubMed ID: 32197047
[No Abstract] [Full Text] [Related]
17. The natural history of lung function after lung transplantation for α(1)-antitrypsin deficiency.
Banga A; Gildea T; Rajeswaran J; Rokadia H; Blackstone EH; Stoller JK
Am J Respir Crit Care Med; 2014 Aug; 190(3):274-81. PubMed ID: 25003824
[TBL] [Abstract][Full Text] [Related]
18. Decline in FEV1 related to smoking status in individuals with severe alpha1-antitrypsin deficiency (PiZZ).
Piitulainen E; Eriksson S
Eur Respir J; 1999 Feb; 13(2):247-51. PubMed ID: 10065663
[TBL] [Abstract][Full Text] [Related]
19. Alpha-1-antitrypsin deficiency: smoking, decline in lung function and implications for therapeutic trials.
Hutchison DC; Cooper D;
Respir Med; 2002 Nov; 96(11):872-80. PubMed ID: 12418584
[TBL] [Abstract][Full Text] [Related]
20. Characteristics of Alpha-1 Antitrypsin-Deficient Individuals in the Long-term Oxygen Treatment Trial and Comparison with Other Subjects with Chronic Obstructive Pulmonary Disease.
Stoller JK; Aboussouan LS; Kanner RE; Wilson LA; Diaz P; Wise R;
Ann Am Thorac Soc; 2015 Dec; 12(12):1796-804. PubMed ID: 26653189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
